Use Nektar Therapeutics media headlines together with your assets to protect against small markets fluctuations as well as to check it against diversification policy that fits your risk preferences.
Jefferies initiates coverage on Nektar Therapeutics (Nasdaq: NKTR) with a Buy rating and $9.50 price target. The firm comments, "Nektar has built a pegylation delivery platform that is the engine of its drug development efforts.
Sacramento Bee - May 3, 2012
By Nektar Therapeutics SAN FRANCISCO, May 2, 2012 -- /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2012.
Nektar Therapeutics Beats Up on Analysts Yet Again - DailyFinance
Growth Strategies for Supergenerics Organizations - Opportunities in ...
Sacramento Bee - Apr 26, 2012
By Reportlinker GBI Research, a leading business intelligence provider, has released its latest research "Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for ...
Nektar to Announce Financial Results for the First Quarter of 2012 on ...
MarketWatch (press release) - Apr 25, 2012
SAN FRANCISCO, April 25, 2012 /PRNewswire via COMTEX/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after the close of US-based financial markets.
Do you like to follow the buying trends of smart money investors? These investors include institutional investors such as hedge fund managers, and because of their experience and access to sophisticated research, their reported stock purchases are very ...
Sacramento Bee - Apr 10, 2012
By Nektar Therapeutics SAN FRANCISCO, April 10, 2012 -- /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16, 2012 from 12:00 pm to 5:00 ...
pharmabiz.com - Apr 4, 2012
Nektar Therapeutics, a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has dosed first subject in a phase I clinical study to evaluate the pharmacokinetics and ...
Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a ... - PR Newswire (press release)
RTT News - Mar 28, 2012
(RTTNews) - Nektar Therapeutics (NKTR: News ) reported that its partner Affymax, Inc. announced that the US Food and Drug Administration, or FDA, has approved OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in ...
Nektar Therapeutics - NKTR - FDA Approval of OMONTYS - Fyxnews
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen - Xconomy
Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS ...
MarketWatch (press release) - Mar 28, 2012
SAN FRANCISCO, March 28, 2012 /PRNewswire via COMTEX/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported that its partner Affymax, Inc. announced that the US Food and Drug Administration (FDA) has approved OMONTYS? (peginesatide) Injection for the ...
Nektar Says Affymax Reveals FDA Approval Of OMONTYS Injection ? Quick Facts - RTT News
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen - Xconomy
FierceBiotech - Mar 27, 2012
Hours after the markets closed last night, Map Pharmaceuticals put out the word that the FDA had stiff-armed its application for the inhalable migraine therapy Levadex, outlining some regulatory issues with the chemistry, manufacturing and controls ...
By Brian Orelli | More Articles The headache caused by not knowing which way the Food and Drug Administration will rule on MAP Pharmaceuticals' (Nasdaq: MAPP ) Levadex is almost over.
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San ...
African Business Review (press release) - 9 hours ago
SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company is consolidating its US-based research scientists at the company's existing San Francisco state-of-the-art R&D center, which is located ...
FierceBiotech - Mar 20, 2012
Nektar Therapeutics ($NKTR) has announced a move to consolidate all of its US research and development at its Mission Bay location in San Francisco.
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San ... - Business Review USA (press release)
Nektar moving 30 research jobs to SF - San Francisco Business Times (blog)
The IN VIVO Blog (blog) - Mar 2, 2012
Abbott is readying for two major steps in its evolution. Most prominently, it's preparing to split its pharma division from its diversified medical products business this year, creating two public companies from one.
Nektar Therapeutics is rated below average in revenue category among related companies. Market size based on revenue of Biotechnology industry is now estimated at about 40.17 Billion. Nektar adds roughly 78.13 Million in revenue claiming only tiny portion of stocks in Biotechnology industry.
Nektar Research Report
Nektar Total Debt
Based on latest financial disclosure Nektar Therapeutics has Total Debt of 228.85 M. This is 81.78% lower than that of Healthcare sector, and 77.52% lower than that of Biotechnology industry, The Total Debt for all stocks is 95.16% higher than the company.
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
